GleamWall
中文EN

ATNM Actinium Pharmaceuticals, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1388320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY130.6%
TTM EPS YoY130.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE55.2%
ROA23.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-2.20x
Accruals ratio76.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$90,000—
R&D expense$21.12M$30.05M
SG&A expense$15.21M$12.08M
Operating income-$36.25M-$42.12M
Pretax income-$33.29M-$38.24M
Net income-$33.89M-$38.24M
EBITDA-$36.07M-$41.92M
EPS (basic)-1.09-1.27
EPS (diluted)-1.09-1.27
Weighted avg. shares (diluted)31.20M30.07M
Balance sheet
Cash & equivalents$48.00M$73.23M
Current assets$49.38M$74.51M
PP&E, net$295,000$364,000
Total assets$51.77M$76.90M
Current liabilities$7.97M$8.15M
Total liabilities$43.94M$44.14M
Shareholders' equity$7.83M$32.76M
Shares outstanding31.20M31.20M
Cash flow statement
Operating cash flow-$24.58M-$33.07M
Capital expenditure$104,000$11,000
Free cash flow-$24.68M-$33.08M
Investing cash flow-$104,000-$11,000
Financing cash flow-$217,000$29.32M
Depreciation & amortization$173,000$197,000
Stock-based compensation$9.19M$5.29M

Free plan shows the latest 2 periods; Pro shows all 25 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.